Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib Maintenance Post Allogeneic HCT in IDH2-Mutated AML
NCT03728335Phase 2Suspended
- Sponsor
- City of Hope
- Start
- Dec 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in acute myeloid leukemia (AML), sponsored by City of Hope. Started Dec 2019; status: suspended.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03728335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728335.